Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T15:51:51.464Z.
Calculation as of: 2026-10-06T15:51:51.464Z.
Quote observation: 2026-10-06T15:50:08.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 2eba736d2827de544c9f141b3fafa3dea8ffa5f0a614b8c2b2ac1915a5af89f6
PE RATIO
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | $250.79M | N/A | N/A | N/A | N/A |
| Quantum-Si incorporated (QSI)vs › | $251.43M | N/A | N/A | N/A | N/A |
| AC Immune S.A. (ACIU)vs › | $257.49M | N/A | 14.47 | 14.47 | 17.60 |
| Anika Therapeutics, Inc. (ANIK)vs › | $258.32M | N/A | 83.73 | 30.92 | 28.56 |
| Nautilus Biotechnolgy, Inc. (NAUT)vs › | $252.60M | N/A | N/A | N/A | N/A |
| Q32 Bio Inc. (QTTB)vs › | $248.68M | 2.99 | 4.27 | 4.27 | 3.78 |
| Greenwich LifeSciences, Inc. (GLSI)vs › | $245.27M | N/A | N/A | N/A | N/A |
| Invivyd, Inc. (IVVD)vs › | $244.52M | N/A | N/A | N/A | N/A |
| Palisade Bio, Inc. (PALI)vs › | $262.97M | N/A | 4.44 | 4.44 | 4.44 |
| Galectin Therapeutics Inc. (GALT)vs › | $244.33M | N/A | 2.96 | 2.96 | 2.96 |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$1.39
Forward EPS (Est.)
$-0.52
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
